Fighting Neurodegeneration with Tau Tangle Blocking: Oligomerix CEO James Moe Explains Finding Genius Podcast, November 24, 2020.
Alzheimer’s biotech firm moves HQ to White Plains Crain’s New York Business Health Pulse, October 13, 2020.
Oligomerix Relocation of Headquarters BioWorld, October 8, 2020.
Oligomerix Awarded a $3.19 Million Grant from NIA BioWorld, September 15, 2020.
Study Might Point Alzheimer’s Research in Whole New Direction U.S. News, 2020.
CDD Spotlight Interview with James Moe – President, CEO and a Co-Founder of Oligomerix ACS Annual Meeting 2015
Oligomerix Raises Series B Round to Mount New Attack on Alzheimer’s Brian Gormley, Dow Jones Venture Wire, May 22, 2013
Targeting Tau For Alzheimer’s Disease and Related Neurodegenerative Disorders Dr. Eliot J. Davidowitz and Dr. James G. Moe. Drug Discovery World, Fall 2012
Tau Gains Popularity as Alzheimer’s Drug Target Brian Orelli, BioWorld® Insight, July 2, 2012, Vol. 20, no. 27.
Oligomerix Targets Tau Protein to Tackle Alzheimer’s Disease Catherine Shaffer, BioWorld® Today, February 8, 2012, Vol. 23, no. 26.
Oligomerix Tau Tapping BioCentury, December 15, 2008